Cabozantinib can improve progression-free survival (PFS) in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC), according to updated results from the CABOSUN trial presented at the ESMO 2017 Congress (abstract LBA 38).
The phase 2 trial compared cabozantinib (Cabometyx, Exelixis) with sunitinib (Sutent, Pfizer) in 157 patients who had intermediate- or poor-risk locally advanced or metastatic clear cell RCC and a performance status of 0 to 2. During the trial,